BioMarin Pharmaceutical Inc. (BMRN)

Over the past six months, BioMarin Pharmaceutical's stock price has experienced fluctuations due to several key events. BioMarin reported $0.12 earnings per share (EPS) for Q3 2025, missing the consensus estimate. BioMarin acquired Inozyme and its late-stage candidate INZ-701 for ENPP1 deficiency for $329.1 million. BioMarin announced its intention to acquire Amicus Therapeutics for $14.50 per share, or $4.8 billion. BioMarin announced the successful pricing of $850 million in senior notes and the syndication of a new $2 billion senior secured term loan facility to fund the Amicus acquisition. There have been several analyst rating adjustments in the past six months.

Specific information regarding demand seasonality for BioMarin Pharmaceutical Inc.'s products and services is not explicitly detailed in the provided search results. The demand for rare disease therapies may be less subject to typical seasonal fluctuations compared to other consumer goods or services, given the critical and ongoing medical needs of the patient populations served.

BioMarin Pharmaceutical Inc. is an American biotechnology company focused on developing and commercializing therapies for life-threatening rare diseases and medical conditions. The company's core business and research focus on enzyme replacement therapies (ERTs) and genetic medicines. BioMarin's major commercial products include VIMIZIM, VOXZOGO, NAGLAZYME, PALYNZIQ, BRINEURA, ALDURAZYME, KUVAN, and ROCTAVIAN.

BioMarin Pharmaceutical Inc. has a global geographic footprint, with offices and facilities in the United States, South America, Asia, and Europe. The company develops and commercializes its therapies internationally, with sales in nearly 80 countries across the United States, Europe, Latin America, the Middle East, and the Asia Pacific.

BioMarin Pharmaceutical has a history of pioneering treatments for conditions that often had no previous therapeutic options. The company has been recognized for its focus on developing and commercializing therapies for rare genetic disorders. However, in the past, BioMarin has faced criticism regarding drug pricing and specific instances of denying access to drugs in clinical trials. Within the past year, no specific events significantly impacting BioMarin Pharmaceutical Inc.'s brand reputation were highlighted in the provided search results.

BioMarin Pharmaceutical Inc. has a diverse ownership structure. As of January 30, 2026, there are 986 institutional owners and shareholders holding a total of 216,647,377 shares. Approximately 52.24% of the company's stock is owned by institutional investors, 0.44% by insiders, and 47.33% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Primecap Management Co/Ca/, Dodge & Cox, State Street Corp, Viking Global Investors Lp, iShares Core S&P Mid-Cap ETF (IJH), Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), and Aqr Capital Management Llc.